Form 4: Pfizer Executive Vice President Lidia Fonseca Reports Stock Transactions

Executive Vice President Lidia Fonseca reports the earn-out of stock appreciation rights and related transactions involving Pfizer common stock.

Summary

• Lidia Fonseca, an Executive Vice President at Pfizer Inc., filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
• On February 27, 2025, Fonseca earned out 72,629 shares of common stock through the settlement of stock appreciation rights at a price of $31.31.
• She also disposed of 1,683 shares to satisfy tax obligations and 68,022 shares to cover the exercise price related to the stock appreciation rights.
• Following these transactions, Fonseca directly owns 41,829 shares of Pfizer common stock.
• The transactions were executed under Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't convey any positive or negative sentiment about the company's performance or prospects.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, as required by Section 16 of the Securities Exchange Act of 1934. It provides transparency into the trading activities of company insiders.

Comparison to Industry Standards

• Executive compensation packages often include stock options and stock appreciation rights to align management's interests with those of shareholders.
• The reporting of these transactions is standard practice and ensures compliance with SEC regulations.
• Similar filings are common among executives at comparable pharmaceutical companies like Johnson & Johnson (JNJ) and Merck (MRK).

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• The filing provides transparency to shareholders regarding executive compensation and stock ownership.

Key Dates